AI Agents for Clinical Reporting: How TealFlow Helps You Build Validated Apps in Hours, Not Weeks
If you're a Statistical Programming Manager, you're familiar with Monday mornings that start with three urgent requests from different Biostatistics leads.
All of them need analytical applications for studies with regulatory deadlines this quarter and your team's sprint backlog is already jammed. Executives push for delivering more while cutting costs and reducing teams. Talk about being between a rock and a hard place.
This is a development bottleneck that’s costing the company millions, and it's far from a basic scheduling problem.
While your team spends weeks building essential but time-consuming safety and efficacy analysis tools, competitors are filing submissions faster and capturing market advantages. Your skilled programmers burn out managing a relentless queue of requests for repetitive analytical applications. Every such application request becomes a two-week development cycle that should be accelerated with specialized tooling, equipped with the reusable patterns and context.
Teams redo the similar dashboards for multiple studies, with no patterns sharing that strain resources and add risk to the submission timeline. Instead, the highly qualified programmers could focus on the complex submission infrastructure and innovative analysis solutions that actually require their specialized expertise.
This is exactly the problem we built an AI agent to solve. TealFlow is one example of Appsilon’s broader agentic AI capability in clinical reporting - an AI agent trained on the `{teal}` framework that generates validated clinical reporting apps fast, without pulling your technical team away from the work that actually needs them.
Let us show you how pharmaceutical companies are using this agentic approach to cut reporting delays, reduce development costs, and accelerate the path to regulatory approval.
The High Cost of Delays in Clinical Reporting
Every week your analytical tools remain unbuilt is a week you don't move the needle.
Let’s talk about math. Pharma companies spend over $2 billion developing a new drug, and every month of delay costs millions in lost revenue. When your biostatisticians can't get the dashboard they need for three weeks, it's a direct threat to your bottom line. According to McKinsey, AI-driven productivity gains in pharma R&D could generate up to $110 billion in annual value across the industry - much of it from reducing exactly these kinds of workflow delays.
But here's the problem: your technical teams weren't hired to build routine analytical apps.
They're engineers, software architects, and platform specialists who should be solving infrastructure challenges. Instead, they're stuck in an endless cycle of building basic Kaplan-Meier curve visualizations and adverse event summaries that any clinical researcher could generate with the right tools.
The real cost hides behind opportunity cost - having your most expensive technical talent focused on routine requests.
This kills innovation.
When it takes three weeks to get a simple analytical tool, your clinical teams can't test multiple hypotheses quickly. They can't explore different endpoints, stratification strategies, or statistical approaches because each iteration requires another formal IT request. By the time they get their first app, the optimal analysis window has already closed.
The effects compound throughout your organization. Medical writers wait for statistical outputs. Regulatory affairs teams delay submission timelines. Study sponsors question whether their trials are progressing. A simple app request becomes a series of delays that touches every aspect of your clinical development process.
No amount of hiring can solve this fundamental workflow problem.
Why R/Shiny Became Trusted in Pharma
In 2026, FDA accepts R-based regulatory submissions, making the path clearer than it was a few years ago.
This shift represents a massive change from the proprietary statistical software that dominated pharmaceutical analysis for decades. Companies like Novo Nordisk, Roche, and Johnson & Johnson have made R central to their regulatory submission strategies, and the results speak for themselves.
Over 60% of pharmaceutical companies have adopted R according to the 2024 Japan Pharmaceutical Manufacturers Association survey. Among the top 23 pharma companies surveyed by Pharmaverse, 20 reported increasing R usage for clinical reporting. Three companies are already doing end-to-end R submissions to the FDA.
But what really changed everything is regulatory acceptance.
The R Submissions Working Group proved that FDA reviewers can successfully evaluate R-generated analyses and outputs. Their pilot projects demonstrated that R-based submissions work in practice. Novo Nordisk was the first to share their successful end-to-end R submission story, and it showed what's possible for other organizations.
R Shiny takes this foundation and makes it interactive. Traditional business intelligence tools only display data, but Shiny applications can both read from and write to databases. This means researchers can modify parameters, update analyses, and save findings within a single application.
The reactive programming model makes Shiny valuable for regulatory review. When FDA reviewers examine submission materials, they can trace through the logical flow of calculations without getting lost in complex code structures. Non-programmers can follow the analysis steps, which matters when clinical statisticians need to validate analytical approaches.
Pilot 4 successfully submitted a Shiny-based package to FDA, giving teams looking at open-source submissions a concrete public reference for how interactive R applications can be packaged for review. Shiny is already in use across pharma for exploratory work, quality checks, and some GxP first-line programming.
Your regulatory team now has a validated route from R analysis to FDA submission that doesn't require expensive proprietary software licenses.
How Agentic AI Changes the Game
Here's the core idea: an AI agent trained on pharmaceutical frameworks can turn a plain-language request into a production-ready analytical application - without an IT ticket, a technical specification, or a three-week wait.
Your clinical researcher types "I need to analyze time-to-event data with Kaplan-Meier curves grouped by treatment arm." The agent generates a strong first version in minutes. Your team then validates and signs off before anything gets near a submission.
TealFlow is the system we built around this idea. It specializes in pharmaceutical frameworks - when your biostatistician mentions survival analysis, the agent suggests specific `{teal}` modules that handle Kaplan-Meier curves, Cox proportional hazards models, and regulatory-compliant visualizations. It understands CDISC data structures, pharmaceutical validation requirements, and FDA submission standards.
The agent works through a three-stage process:
- Analyzes your clinical dataset and requirements
- Maps those needs to validated teal components
- Generates complete, production-ready code that follows pharmaceutical industry standards
Your teams can refine applications through conversation. Researchers can say "Can you add a filter for different dose groups?" or "I need to exclude patients who discontinued before day 30." The agent adapts the application in real-time while maintaining code quality and compliance standards.
Each interaction improves both your immediate application and the agent's understanding of your specific analytical workflows. It learns your coding standards, validation requirements, and analytical preferences.
It generates reviewer-ready applications with proper documentation, clear variable naming, and modular functions. Your validation team can review and approve the code using the same processes they use for manually-written applications.
What this really means is that your clinical researchers gain analytical independence. They don't have to rely on your technical team's availability. And your tech team can focus on complex infrastructure projects that require their specialized expertise.
Strategic Benefits for Pharma Companies
Once your organization adopts this agentic approach, your entire workflow around clinical data analysis will change. Here are three benefits you'll see.
Faster time to insight
Clinical researchers get the apps they need in hours. Your biostatistician describes their survival analysis requirements in plain language and gets a working dashboard before lunch. No IT tickets, no three-week development cycles, no missed regulatory deadlines because someone couldn't act on the ticket in time.
Faster reporting leads to faster filings, from accelerated market entry. Each month you shave off your regulatory submission timeline translates directly to millions in additional market exclusivity revenue.
This approach lets you be the company that uses data to make better and faster decisions while your competitors are still stuck on their first statistical analysis.
Improved collaboration
Reducing this bottleneck lets technical teams focus on strategic projects. Your senior developers stop building routine analytical dashboards. You get more strategic value from your most expensive technical talent.
Cross-functional workflows improve when researchers control their own tools. Medical writers can explore different data cuts for submission documents. Regulatory affairs teams can validate statistical approaches using the same interactive applications that generated the analyses.
No more email chains requesting minor chart modifications or waiting days for simple parameter changes.
Reduced compliance risk
The agent generates code that follows pharmaceutical industry standards and has already passed FDA review through the R Submissions Working Group pathway. Your validation team can review applications using established procedures instead of creating new compliance frameworks.
The review-ready outputs can reduce compliance risk compared with one-off custom-coded solutions. Your regulatory team knows that applications built on this framework follow the same submission pathway that companies like Novo Nordisk and Roche have proven with the FDA.
Industry Validation
The pharmaceutical industry's most respected companies have already proven that open-source R solutions work for regulatory submissions.
Roche leads the transformation with their end-to-end R submission strategy. Roche presented an end-to-end R submission for a new drug application to the FDA, EMA, and NMPA, using OCEAN and a package stack in which the majority of tools were open-source Pharmaverse packages. Roche developed the `admiral` package for internal data standards and contributed the `{teal}` framework that TealFlow builds upon. Their regulatory teams now have a validated pathway from R analysis to FDA approval.
Novo Nordisk demonstrated that R-based submissions work in practice. Their end-to-end R submission to the FDA proved that regulatory reviewers can successfully evaluate R-generated analyses and outputs. When Novo Nordisk shared their success story, they showed other pharmaceutical companies a concrete path to follow.
Johnson & Johnson joined the R submission movement with their own successful FDA filings using open-source tools. Their experience added to the growing body of evidence that R-based approaches meet regulatory standards and provide more flexibility than proprietary statistical software.
Pfizer contributes to open-source statistical computing through multiple repositories that demonstrate how pharmaceutical companies can build upon shared statistical frameworks. Their Open Repositories highlight the strategic value of collaborative development.
All of these are industry leaders who proved R works for regulatory submissions. The R Submissions Working Group documented these successes and created a clear roadmap that other pharmaceutical companies can follow.
When your team uses an AI agent to generate `{teal}` applications, you're building on the same validated foundation these companies used for FDA submissions.
Looking Forward: An Ecosystem of Instantly Customizable, Validated Apps
TealFlow represents the beginning of a broader transformation in pharmaceutical application development.
The future brings an entire ecosystem of R applications that are already validated and can be customized in minutes - not weeks or months.
Imagine having access to a library of pre-built clinical reporting applications - survival analysis tools, biomarker exploration dashboards, safety monitoring systems - that can be customized instantly through conversation. Your teams start with validated templates and adapt them to specific trial requirements in no time.
Organizations that can generate insights fastest gain advantages in drug development timelines and regulatory success rates. AI agents can now understand pharmaceutical workflows as deeply as your most experienced biostatisticians.
What This Means for Your Clinical Reporting
Agentic AI addresses the persistent gap between what clinical researchers need and what technical teams can deliver within reasonable timeframes.
When biostatisticians can get a strong first version of a validated application in minutes - then have their team review and sign off - your technical teams can focus on complex infrastructure while researchers gain analytical independence. Companies like Novo Nordisk and Roche proved that R-based submissions work with FDA reviewers. This agentic approach just builds on that validated foundation.
Want to explore what an AI agent could do for your clinical reporting workflow?
Whether TealFlow fits your use case or you need a custom-built agent, talk to the Appsilon team about what's possible. You can also explore our collection of resources and case studies.